Navigation Links
Amarillo Biosciences Issues Corporate Update

AMARILLO, Texas, Oct. 14, 2011 /PRNewswire/ -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today provided an update on company activities.

Oral Interferon Phase 2 Hepatitis C Study Nearing CompletionABI's oral interferon research continues. Results from a Phase 2, dose-ranging study of oral interferon for the prevention of relapse in hepatitis C patients are expected in the first quarter of 2012. A Phase 2 study of oral IFN, in combination with Tamiflu, for the treatment of influenza infection will be conducted during the upcoming flu season in Taiwan. Results are expected in the third quarter of 2012.

New Oral Interferon Studies Planned in Hepatitis B and CancerTwo new oral interferon studies are expected to start in 2012. The first will be a Phase 2 study for treatment and prevention of relapse in patients with chronic hepatitis B infection. The second will be a pilot trial to evaluate oral interferon as adjunctive therapy for certain types of cancer.

Launch of Product to Enhance Health of Animals in Shelters Planned by Year's EndThere are approximately 3,500 animal shelters in the United States. Whenever animals from different sources and backgrounds, and often with an incomplete vaccination history, are placed into these shelters, upper respiratory illness (URI) with severe cough and fever is a common occurrence. Digestive tract infections also frequently develop in these shelters. Both URI and diarrhea cause severe illness and an unacceptably high rate of death in sheltered animals.

ABI's goal is to provide a product to help address these common health problems afflicting the nation's animal shelters. More than 20 years of research and observations have resulted in the creation of an inexpensive oral formulation that can be given to companion animals upon arrival at shelters to improve their health and enhance their immunity. Product launch is expected by the end of the year.

About Amarillo Biosciences
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 6% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza and hepatitis C. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" and "Item 7A. Qualitative and Quantitative Disclosures about Market Risk" of the Company's Form 10-K for the fiscal year ended December 31, 2010. Investor Relations: Philippe Niemetz

PAN Consultants, Ltd.

Tel: 800-477-7570; 212-344-6464

Fax: 212-618-1276Investor Inquiries: Josh Tyrell

Interactive Business Alliance, LLC


Tel: 866-525-4714

SOURCE Amarillo Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amarillo Biosciences Teams with Animal Shelters to Improve Health and Enhance Immunity of Cats and Dogs
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Milestone Biosciences, LLC Further Strengthens Executive Management Team
6. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
7. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
8. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
9. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
10. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
11. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
Post Your Comments:
(Date:12/1/2015)... ... 01, 2015 , ... The American Society of Gynecologic Laparoscopists, ... Mathews will join fellow surgeons in the shared pursuit of ÔÇťadvancing minimally ... urogynecologist, founder of Plano Urogynecology Associates and Fellow of the American College ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... Manufacturing Practice (GMP) 10000 in the Santiago Marriott. The Global Stem Cells Group ... by a world-class team of qualified medical researchers and practitioners, experienced in administering ...
(Date:11/30/2015)... , Nov. 30, 2015  Culprits beware, a ... chemistry professor Jan Halámek, is taking crime scene ...   -->   ... --> --> ... have discovered a straightforward concept for identifying whether ...
(Date:11/30/2015)... , Nov. 30, 2015  Champions Oncology, Inc. ... and services to personalize the development and use of ... Chief Executive Officer, will be presenting at the LD ... 4:30pm Pacific Standard Time (PST).  The conference, held at ... Los Angeles, CA , will feature 200 small/micro-cap ...
Breaking Biology Technology:
(Date:11/18/2015)... ALBANY, New York , November 18, 2015 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2021. According to ... bn in 2014 and is anticipated to reach US$29.1 ... 2015 to 2021. North America ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
Breaking Biology News(10 mins):